International
grindeks.eu
Latvia
grindeks.lv
Moldova
grindeks.md
Choose your country
Grindeks search
International
Company
Products
Services
R & D
Investors
Careers
News
Contacts
Company
Products
Services
R & D
Investors
Careers
News
Contacts
News
← Back to overview
Turnover of Grindeks reaches 71.5 million euro in the first six months...
30.08.2018
From Individual Research Projects to Strategic Long-Term Cooperation: ...
22.08.2018
Grindeks concludes land purchase agreement for innovation centre devel...
08.08.2018
The Minister of Finance of the Republic of Latvia visits Grindeks
31.07.2018
Turnover of Grindeks reaches 34.8 million euro in the first three mont...
31.05.2018
Chairman of the Grindeks’s Council Kirovs Lipmans named the winner o...
22.05.2018
Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10...
07.05.2018
Grindeks shares the good practice in EU campaign Healthy Workplaces Ma...
25.04.2018
Grindeks awarded Latvian biggest exporter in 2017
09.04.2018
Show archive
2018
Juris Bundulis re-elected as the Chairman of the Board; Ph.D. Juris Hmelnickis to become a Board Member of JSC Grindeks
09/01
In 2018 Grindeks forecasts at least 10% increase in turnover
17/01
Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.3 million euro
28/02
Grindeks awarded Latvian biggest exporter in 2017
09/04
Grindeks shares the good practice in EU campaign Healthy Workplaces Manage Dangerous Substances
25/04
Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.0 million euro
07/05
Chairman of the Grindeks’s Council Kirovs Lipmans named the winner of the IIHF Paul Loicq Award
22/05
Turnover of Grindeks reaches 34.8 million euro in the first three months of 2018; profit – 3.2 million euro
31/05
The Minister of Finance of the Republic of Latvia visits Grindeks
31/07
Grindeks concludes land purchase agreement for innovation centre development
08/08
From Individual Research Projects to Strategic Long-Term Cooperation: Grindeks and Latvian Institute of Organic Synthesis Sign Agreement
22/08
Turnover of Grindeks reaches 71.5 million euro in the first six months of 2018; profit – 6.7 million euro
30/08
2017
Two Grindeks subsidiaries receive Russian Good Manufacturing practice certificates
25/01
Grindeks concludes an agreement on the project implementation funded by EU
25/01
On Grindeks results in 2016
28/02
Grindeks is among winners of a competition The Trademark 2016
27/04
On Grindeks audited results in 2016
28/04
On Grindeks results in the first three months of 2017
29/05
Grindeks ranks 6th on Latvian Business Reputation Top 2017
08/06
Annual Report and Corporate Social Responsibility Report 2016
17/07
Turnover of Grindeks reaches 68.3 million euro in the first half-year of 2017; profit – 6.5 million euro
28/08
Grindeks receives Russian Good Manufacturing Practice certificate
31/08
Meet us in Messe Frankfurt at CPhI Worldwide 2017
06/10
Turnover of Grindeks reaches 95.9 million euro in the first nine months of 2017; profit – 6.5 million euro
27/11
Healthy New Year 2018!
22/12
2016
On changes in the Board of JSC Grindeks
04/01
Janis Romanovskis to become a Board Member of JSC Grindeks
12/01
Notification on changes in the composition of the Supervisory Council of JSC Grindeks
13/01
On Grindeks results in 2015
26/02
Grindeks: Meldonium should not be included in the Prohibited list
09/03
Experts: There’s no evidence that meldonium enhances performance
08/04
Mildronate® is not a doping
18/04
On Grindeks audited results in 2015
29/04
Notification on convocation of joint stock company Grindeks Annual General Meeting of shareholders
06/05
Draft Resolutions of Annual General Meeting of Shareholders of JSC Grindeks to be held on 7 June 2016
24/05
On Grindeks financial results in the three months of 2016
27/05
Decisions of Annual General Meeting of Shareholders of joint stock company Grindeks
07/06
Annual Report and Corporate Social Responsibility Report 2015
04/07
Grindeks financial results in the first half year of 2016
26/08
JSC Grindeks and World Anti-Doping Agency have agreed on cooperation
14/09
Grindeks awards the most outstanding Latvian scientists and grants D.H.Grindel award
13/10
The State JSC “Privatisation Agency” invites to join webinar on the auction of state-owned shares of JSC Grindeks
26/10
On Grindeks financial results in the first nine months of 2016
25/11
On Grindeks manufacturing expansion
02/12
Grindeks will reward best chemistry teachers
07/12
Grindeks Christmas game
20/12
Amitriptyline-Grindeks received Russian Pharma Awards 2016 prize
20/12
2015
Juris Bundulis has been reelected as the Chairman of the Board of JSC Grindeks for another term of the office
09/01
Professor Andrejs Ērglis receives D.H.Grindel award
09/02
JSC Grindeks unaudited interim report for 12 months of 2014
27/02
JSC Grindeks audited financial results for twelve months of 2014
30/04
Notification on convocation of joint stock company Grindeks Annual General Meeting of shareholders and DRAFT RESOLUTIONS
11/05
Grindeks has started UDCA preparation export to Russia and Georgia
27/05
On Grindeks financial results in the first quarter of 2015
29/05
RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company Grindeks to be held on 12 June 2015
12/06
Denomination of shares from lats to euro
30/06
The Annual Report and Corporate Social Responsibility Report 2014 of JSC Grindeks
06/07
Notification on changes in qualifying holdings of joint stock company Grindeks
17/07
On Grindeks financial results in the first six months of 2015
28/08
The Governor of Ulyanovsk Oblast Sergey Morozov visits Grindeks
04/09
Grindeks supplies oxytocin injections to the World Health Organization
24/09
Grindeks receives the Energy management system certification LVS EN ISO 50001:2012 (ISO 50001:2011)
09/10
Company’s announcment
10/10
On changes in the Board of JSC Grindeks
12/10
Grindeks and “Kalceks” participate in the international exhibition “CPhI Worldwide 2015”
13/10
On Grindeks financial results in the nine months of 2015
27/11
The Financial Calendar of JSC Grindeks for the year of 2016
18/12
2014
East Capital AB has disposed the holding of the share capital of JSC Grindeks
02/02
ABLV Private Equity Fund 2010, KS has acquired 22.66% of the share capital of JSC Grindeks
05/02
DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of JSC Grindeks to be held on 10 June 2014
30/04
Notification on convocation of JSC Grindeks Annual General Meeting of shareholders and draft resolutions
30/04
On Grindeks audited financial results for 2013
30/04
On inclusion of additional items in the agenda of JSC Grindeks Annual General Meeting of shareholders and draft resolution proposals submitted by shareholder
19/05
Supplemented DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company Grindeks to be held on 10 June 2014
27/05
On JSC Grindeks financial results for the first quarter of 2014
30/05
About the JSC Grindeks purchase agreement of “HBM Pharma” s.r.o.
30/05
Grindeks invests 2.6 million euros in Quality Control Laboratory
05/06
Resolutions of Annual General Meeting of Shareholders of JSC Grindeks held on 10 June 2014
10/06
Notification on changes in the composition of Supervisory Council of JSC Grindeks
12/06
Sergejs Bataļins has been elected as a Member of the Board of JSC Grindeks
03/07
The Annual Report and Corporate Social Responsibility Report 2013 of JSC Grindeks
08/07
Notification on changes in the composition of Audit Committee of JSC Grindeks
28/08
JSC Grindeks financial results for the first half-year of 2014
29/08
Grindeks greets participants of the International Chemistry Olympiad and their teachers
02/09
Announcement on JSC Grindeks shareholders meeting
05/09
Notification on convocation of joint stock company Grindeks Extraordinary General Meeting of shareholders
21/09
Draft resolutions submitted by shareholder of items included in the agenda of joint stock company Grindeks Extraordinary General Meeting of shareholders
24/09
Vadims Rabsa has been reelected as the Member of the Board of JSC Grindeks for another term of the office
13/10
DRAFT RESOLUTIONS of the Extraordinary General Meeting of Shareholders of joint stock company Grindeks to be held on 11 November 2014
28/10
RESOLUTIONS of the Extraordinary General Meeting of Shareholders of joint stock company Grindeks held on 11 November 2014
11/11
Regarding composition of the Supervisory Council of joint stock company Grindeks
12/11
The scientist Maija Dambrova receives the “Golden Owl” for outstanding performance in science
14/11
Notification on convocation of joint stock company Grindeks Extraordinary General Meeting of shareholders
20/11
Riga Stradins University signs the cooperation agreement with Grindeks
27/11
On JSC Grindeks financial results for nine months of 2014
28/11
DRAFT RESOLUTIONS of the Extraordinary General Meeting of Shareholders of joint stock company Grindeks to be held on 22 December 2014
08/12
The Financial Calendar of JSC Grindeks for the year of 2015
22/12
RESOLUTION of the Extraordinary General Meeting of Shareholders of joint stock company Grindeks held on 22 December 2014
22/12
2013
Explanation of the data of State Agency of Medicines of Latvia
25/02
Grindeks concluded 2012 with a record-high profit of 9.6 million lats
28/02
Grindeks turnover continues to grow
03/04
Grindeks named among 25 most influental Latvian exporters
03/04
Grindeks continues to invest in its development
04/04
The Ambassadors of Japan to Latvia and to Finland visit JSC Grindeks
10/04
JSC Grindeks listed as one of the most influential Latvian exporters
11/04
Grindeks turnover amounted to 82.7 million lats: audited financial results
30/04
Notification on convocation of joint stock company Grindeks Annual General Meeting of shareholders
30/04
DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of JSC Grindeks to be held on June 4, 2013
21/05
Profit of Grindeks in the first quarter of 2013 – 2.2 million lats
31/05
RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company Grindeks held on June 4, 2013
06/06
Grindeks profit disposition statement for the year 2013
20/06
Grindeks named among 25 most influental Latvian exporters
03/07
Grindeks Annual Report 2012 and Corporate Responsibility Report 2012
05/07
Grindeks gains new export opportunities to the U.S.
12/07
Profit of Grindeks in the first half of the year 2013 – 4.1 million lats
30/08
JSC Grindeks receives the Russian ГОСТ (GOST) certificate of quality ISO 9001-2011
16/09
Grindeks participates in the international exhibition “CPhI Worldwide 2013” in Frankfurt
17/10
Grindeks invests 1.6 million lats in the Quality control laboratory
27/11
Profit of Grindeks in the first nine months of 2013 – 5.4 million lats
02/12
2012
Juris Bundulis appointed as Chairman of the Board of JSC Grindeks
09/01
Grindeks: currently we have 20 new products under development
06/02
Grindeks: EU-funded Competence Centres Program is important to the development of Latvia’s national economy
07/02
On Grindeks financial results for 2011
24/02
Latvian Minister of Health Ingrīda Circene visits JSC Grindeks
01/03
DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company Grindeks to be held on June 19, 2012
26/04
Notification on convocation of joint stock company Grindeks Annual General Meeting of shareholders
27/04
Grindeks project “Profession Days for Pupils” is successfully concluded
11/05
Profit of Grindeks in the first quarter of 2012 – 1.64 million lats
25/05
Grindeks participates in the conference “CEO Meets Investor” in Vilnius
29/05
Grindeks antidepressant receives a prestigious award in Russia
31/05
RESOLUTIONS of Annual General Meeting of Shareholders of JSC Grindeks held on June 19, 2012
19/06
JSC Grindeks Annual Report 2011
04/07
Grindeks Corporate Social Responsibility Report of 2011
05/07
Grindeks and the Latvian University will jointly create a pharmaceutical research, development and production infrastructure
09/07
AS LHV Varahaldus has acquired 5.13% of the share capital of JSC Grindeks
09/07
Notification on election of auditor of Joint stock company Grindeks and determination of the remuneration for auditor
16/07
Grindeks opens representative office in Armenia
16/07
Vice Minister of Health of the People’s Republic of China Zhang Mao is supporting the activities of Grindeks in the People’s Republic of China
30/07
Grindeks becomes a supporter of International Medical Meeting in Riga (IMM-Riga 2012)
10/08
Profit of Grindeks in the first half-year of 2012 – 3.7 million lats
24/08
Chairman of the Board of Grindeks Juris Bundulis delivers presentation in the international conference “Life Sciences Baltics 2012” in Vilnius
13/09
Grindeks will participate in the international exhibition “CPhI Worldwide 2012” in Madrid
17/09
The delegation of Japanese entrepreneurs visiting JSC Grindeks
21/09
Capacious ointment and gel production of Grindeks
10/10
Grindeks fund “For the Support of Science and Education” in cooperation with LAS awards scientists with “Golden Owls” and “Silver Owls”
08/11
Profit of Grindeks in the first nine months of 2012 – 5 million lats
26/11
Grindeks announcement on turnover and profit prognosis in the year of 2013
28/11
Grindeks unveils manufacturing unit of ointments and gels
28/11
Two leading Latvian companies in their sector receive international prize for excellence in quality
06/12
Environmental Control Laboratory of Grindeks receives ISO 17025 certificate
11/12
2011
Grindeks receives the award for the Best Investor Relations Online in the Baltic countries and the Best Investor Relations in Latvia
21/01
Grindeks successfully continues registration of Mildronate® in China
27/01
Grindeks establishes new anti-cancer manufacturing unit
04/02
Notification on losing significant holding
07/02
On Grindeks financial results for 2010
25/02
Representatives of European Commission, Latvian Investment and Development Agency and Latvian Finance Ministry visit JSC Grindeks
29/03
Corporate Governance Report 2010 of JSC Grindeks
28/04
On Grindeks audited financial results for 2010
28/04
Notification on convocation of joint stock company Grindeks Annual General Meeting of shareholders
20/05
Profit of Grindeks in the first quarter of 2011 – 1.5 million lats
27/05
DRAFT RESOLUTIONS of Annual General Meeting of Shareholders of joint stock company Grindeks to be held on June 22, 2011
08/06
Grindeks vitamins return in packaging developed by students of Art Academy of Latvia
10/06
Grindeks invites media to opening ceremony of UDCA manufacturing unit on 16 June 2011
13/06
Grindeks will organize symposium in XXIII Nordic-Baltic Congress of Cardiology
15/06
JSC Grindeks unveils UDCA active pharmaceutical ingredient’s manufacturing unit
16/06
UDCA active pharmaceutical ingredient’s manufacturing unit of JSC Grindeks will increase turnover
17/06
Resolutions of Annual General Meeting of Shareholders of joint stock company Grindeks to be held on June 22, 2011
22/06
JSC Grindeks Annual Report 2010
22/07
Profit of Grindeks in the first half-year of 2011 – 4.26 million lats
25/08
Grindeks will participate in the exhibition „CPhI Worldwide 2011”
21/09
JSC Grindeks original preparation Mildronate® GX recognised as “The Cardiological Medication of the Year” in Ukraine
03/10
Vadims Rabsa has been reappointed as the Member of the Board of Grindeks for the next three years
06/10
Grindeks participates in the international exhibition “CPhI Worldwide 2011” in Frankfurt
24/10
Profit of Grindeks in the first nine months of 2011 – 5.85 million lats
24/11
On changes in JSC Grindeks Management
24/11
On the choice of the new Chairman of the Board of JSC Grindeks
19/12
JSC Grindeks Foundation “For the Support of Science and Education” awards premiums to teachers, higher educational institutions` teaching staff and educational institutions
29/12
On publishing of JSC Grindeks non-audited interim consolidated financial statements in 2012
29/12
2010
On publishing of JSC Grindeks non-audited interim consolidated financial statements in 2010
04/01
JSC Grindeks information regarding injections manufacturing plant in Slovakia
07/01
Clinical trial on Mildronate® is successfully finished
03/02
JSC Grindeks received approval of co-financing from ERDF for construction of UDCA manufacturing unit
12/02
JSC Grindeks informs on publication in information portal BNS
15/02
On Grindeks Financial Results in 2009
26/02
JSC Grindeks signs agreement with Investment and Development Agency of Latvia on co-financing of 2.8 million lats from ERDF
26/02
Notification on obtaining significant holding
12/04
Notification on losing significant holding
12/04
Grindeks plans to increase its turnover to 70 million lats this year
13/04
Grindeks has left the Latvian Employers Confederation
14/04
Notification on convocation of joint stock company GRINDEKS Annual General Meeting of shareholders
16/04
On Grindeks Audited Financial Results in 2009
28/04
Corporate Governance Report 2009 of JSC Grindeks
28/04
Draft resolutions of Annual General Meeting of Shareholders of JSC Grindeks
11/05
Resolutions of Annual General Meeting of Shareholders of JSC Grindeks
25/05
Resolutions of Annual General Meeting of Shareholders of JSC Grindeks
25/05
Profit of Grindeks in the first quarter of 2010 is 1.4 million lats
27/05
Grindeks plans to earn 10 million lats this year
16/06
JSC Grindeks Annual Report 2009
29/06
JSC Grindeks fights with unfair competition
28/07
Grindeks agreed with Latvian Institute of Organic Synthesis on closer cooperation
18/08
Grindeks achieves 4.1 million lats profit in first half-year of 2010
26/08
Grindeks participates in the exhibition „CPhI Worldwide 2010”
29/09
Grindeks receives the Baltic Corporate Excellence Award 2010
05/10
Notification on obtaining significant holding
29/10
Notification on alienation of significant holding
02/11
JSC Grindeks will closer cooperate with Latvian Institute of Organic Synthesis
11/11
Profit of Grindeks in the first nine months of 2010 – 5.2 million lats
26/11
Notification on acquisition of significant holding
08/12
Grindeks won the prize “Leading Exporter”
13/12
On publishing of JSC Grindeks non-audited interim consolidated financial statements in 2011
21/12
On development of JSC Grindeks Group
29/12
2009
JSC Grindeks opens the new final dosage forms plant
21/01
Experts opinion – use of Mildronate® injections is safe
25/03
Grindeks supplies oxytocin for the global health care project
02/04
Outsourcing: do more with less!
02/04
JSC Grindeks will open industrial sewage purification plan
01/06
Grindeks emphasizes, that the price of the Mildronate in Latvia is smaller than in other countries
21/09
Grindeks participates in the exhibition „CPhI Worldwide 2009”
30/09
Grindeks launches antiviral medication Rimantadine-Grindeks
12/11
New Rimantadine-Grindeks already available in chemistry shops
10/12
2008
Grindeks plans to finish the new production unit for Final dosage forms
17/01
Grindeks supports adjudging of “Annual Awards in Medicine”
12/02
Respectable USA Research Center has chosen oxytocin produced by Grindeks
26/03
Mildronāts® – the most exportable product from Latvia in 2007
26/03
Environmental protection topic is discussed on the World Health Day
07/04
Grindeks JSC is opening new representative office in Uzbekistan
17/04
Vitālijs Skrīvelis is affirmed as chairman of the board of the Association of Latvian Chemical and Pharmaceutical Industry
29/04
JSC Grindeks celebrates Ridgepole celebrations of the new Purification plant building
03/06
JSC Grindeks has been awarded the „Baltic Corporate Excellence Award 2008”
04/06
Grindeks participates in the exhibition „CPhI Worldwide 2008”
24/09
Grindeks organizes an international conference on the World Mental Health Day
10/10
JSC Grindeks is awarded for the best investor relations online in the Baltic Countries
05/12
The Union of employees of JSC Grindeks signs a Collective Labour Agreement for 2008
17/12
2005
Grindeks plans to double its production capacities
01/03
JSC Grindeks informs about the invitation to repeatedly submit its application for the acquisition of the shares of pharmaceutical company “Jelfa S.A”
12/10
JSC company’s Grindeks Information for Riga Stock Exchange
16/11
2004
The repeated extraordinary shareholders’ meeting will take place on February 10, 2004 at 10.00
21/01
A gift of scientific literature to the Latvian Academic Library
01/03
Grindek presents a bronchoscope to Gaiļezera Hospital to mark its 25th birthday
12/03
Profit of Grindeks last year reaches the level of one million lats
15/03
Mildronate – one of the most exported Latvian products!
26/03
Easter present of medicines for Latvia’s underprivileged
02/04
Grindeks’ subsidiary company, Tallinn Pharmaceutical Plant celebrates its 90th anniversary!
04/05
Grindeks chairman receives a high international award
03/06
Squeeze-out of the shareholding from the Tallinn Pharmaceutical Plant minority shareholders
23/07
Grindeks supports the performance by Russia’s rising star, Pelageja at the legendary Latvian music festival, Liepājas Dzintars.
08/08
Valdis Jākobsons selected as Honorary Patron of the 13th Congress of the Association of European Medicine History Museums
08/08
About extraordinary general meeting of shareholders
16/08
Grindeks issues awards to young chemists
06/10
Scientists and pharmacists receive Grindelis Medal
08/10
Grindeks honours outstanding chemistry teachers
05/11
Gold Owl and Silver Owl awards presented to notable Latvian scientists
18/12
2003
Grindeks turnover rose by 32% last year
11/02
Grindeks donates computers to the Non-Governmental Organisations’ Centre
21/02
Grindeks receives GMP certificate
23/03
First quarter operating results
25/04
Increased turnover during the first half year
25/07
Establishment of a Baltic pharmaceutical company
28/07
Recognition for young chemists
16/09
Grindeks receives the Good Practice Award
17/10
Operating results during the first 9 months of this year
24/10
Grindeks commence a new education support programme
06/11
Gratitude to the best chemistry teachers
28/11
Good Practice Award Winners are invited to Spain
01/12
Grindeks presents gifts to the Latvian Children’s Foundation and the Red Cross
11/12
Grindeks and the Latvian Academy of Sciences present awards to Latvian scientists
20/12
Name Surname
Your email
Set gender
---
Female
Male
Set birth date - dd/mm/yyyy
City
Country
Join Newsletter
Thank you for your submission!